Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kamada (IL:KMDA)
:KMDA
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.19Last Year’s EPS
15.69Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 12, 2025
|% Change Since: -5.90%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue and EBITDA growth. The company showcased robust cash flow and strategic expansions in plasma collection and biosimilar products. However, there are ongoing challenges with FDA discussions and increased operating expenses. Overall, the highlights significantly outweigh the lowlights, indicating positive momentum.Company Guidance
During Kamada's Q3 2024 earnings call, the company announced a robust financial performance with total revenues of $41.7 million, reflecting a 10% year-over-year increase. Adjusted EBITDA for the quarter reached $8.8 million, marking an 11% growth from the previous year. For the first nine months, revenues rose by 15% to $121.9 million, while adjusted EBITDA surged by 43% to $25.4 million, maintaining a 21% revenue margin. The company revised its full-year adjusted EBITDA guidance upward to between $32 million and $35 million, a 12% increase from prior guidance, and reaffirmed its revenue projection of $158 million to $162 million. Kamada reported strong cash flow with $37.2 million generated from operations, leading to a cash balance of $72 million. The call highlighted ongoing strategic initiatives, including expanding plasma collection centers and advancing the Phase III trial for the Inhaled AAT product, underscoring the company's continued commitment to double-digit growth.Revenue and EBITDA Growth
Total revenues for Q3 were $41.7 million, a 10% increase compared to Q3 2023, and adjusted EBITDA was $8.8 million, an 11% increase. For the first 9 months, revenues were up 15% to $121.9 million, and adjusted EBITDA was $25.4 million, up 43% over the prior year.
Cash Flow and Financial Strength
Generated $37.2 million of cash from operations in the first 9 months, ending Q3 with $72 million in cash. This financial strength supports business development and M&A opportunities.
Expansion of Plasma Collection Centers
Opened a new plasma collection center in Houston with a capacity of over 50,000 liters annually, and construction of a third site in San Antonio is underway.
Biosimilar Product Launch
Launched the first biosimilar product in Israel, with several others in the pipeline, expected to reach peak potential annual sales of $30 million to $34 million.
Market Leadership in KEDRAB and CYTOGAM
Increased sales of KEDRAB and CYTOGAM, driving revenue growth, with KEDRAB holding a 40-50% market share.
---
IL:KMDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IL:KMDA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 12, 2025 | 2900.00 | 2813.00 | -3.00% |
| Nov 13, 2024 | 2284.00 | 2295.00 | +0.48% |
| Aug 14, 2024 | 2026.00 | 2024.00 | -0.10% |
| May 08, 2024 | 2076.00 | 2131.00 | +2.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Kamada (IL:KMDA) report earnings?
Kamada (IL:KMDA) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Kamada (IL:KMDA) earnings time?
Kamada (IL:KMDA) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Kamada stock?
The P/E ratio of Kamada is N/A.
What is IL:KMDA EPS forecast?
IL:KMDA EPS forecast for the fiscal quarter 2025 (Q1) is 0.19.
---